Lateral flow rapid tests are one of the most well established diagnostic solutions on the market and this $5bn market is expected to grow by a Compound Annual Growth Rate (CAGR) of 8.2% from 2017 to 2022.
The versatility of lateral flow technology is a major factor in its widespread adoption. For example, lateral flow tests can be used to provide qualitative or quantitative results for single target or multiplex assays. This flexibility has led to lateral flow being used across a variety of sectors including the clinical, pharmaceutical, animal health, agriculture and environmental markets.
First of all, it is important to understand the benefits of using lateral flow technology. Here are some of the reasons why our customers have incorporated lateral flow immunoassays (LFIAs) into their business activities.
In our experience companies require assay development and manufacture because the test they need is not on the market, is not available to them commercially or they want to transfer another diagnostic method, such as ELISA, to lateral flow.
Before actively engaging in assay development and manufacture it is worth carrying out a project assessment.
But, what do you need to do and consider before incorporating lateral flow technology into your business activities? The following tasks will help to guide you.
The simple answer is, most! With the advancement in technology and development and manufacturing techniques, lateral flow tests can be used across both regulated and non-regulated markets.
If you have any questions about lateral flow rapid tests and their usability please contact us on +44 (0) 1904 606082 or at [email protected].